NM
NMRA.US Neumora Therapeutics, Inc.
- Market cap
- USD 69.4M
- P/E
- -
- P/B
- 1.81x
- ROE
- -433.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NMRA.US undervalued?
Graham numberThe Graham number of Neumora Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neumora Therapeutics, Inc. fundamental analysis
No fundamental analysis for Neumora Therapeutics, Inc. yet.
Neumora Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients …
Full company profileNeumora Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neumora Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -1.55M | -2.70M | -668K | - | -5.00M | - |
| Operating Income | - | -95.5M | -237M | -136M | -188M | -263M | -241M | -190M |
| EBITDA | - | -95.4M | -237M | -130M | -235M | -243M | -233M | -187M |
| Net Income | - | -99.3M | -237M | -131M | -236M | -244M | -237M | -193M |
| EPS | - | -0.65 | -1.56 | -0.86 | -1.49 | -1.53 | -1.45 | -1.04 |
| Balance Sheet | ||||||||
| Total Assets | 0.00 | 198M | 429M | 426M | 496M | 317M | 191M | 125M |
| Total Liabilities | 21.0K | 292M | 755M | 873M | 27.1M | 29.9M | 87.2M | 80.7M |
| Shareholders' Equity | -21.0K | -94.4M | -325M | -447M | 469M | 287M | 104M | 44.5M |
| Cash & Short-term Investments | 0.00 | 192M | 409M | 372M | 454M | 308M | 183M | 117M |
| Total Debt | - | 2.05M | 2.05M | 8.44M | 5.23M | 1.85M | 477K | 340K |
| Cash Flow | ||||||||
| Operating Cash Flow | -26.8M | -26.8M | -75.4M | -115M | -163M | -183M | -206M | -172M |
| Capital Expenditure | 1.30M | 1.30M | 817K | 511K | 117K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -28.1M | -76.2M | -115M | -163M | -183M | -206M | -172M |
| Ratios | ||||||||
| ROE | - | - | - | - | -50.3% | -84.9% | -228.1% | -433.7% |
| ROA | - | -50.2% | -55.3% | -30.7% | -47.5% | -76.9% | -124.0% | -154.2% |
| Debt to Equity | - | - | - | - | 0.01x | 0.01x | 0.00x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Neumora Therapeutics, Inc. dividends
Neumora Therapeutics, Inc. has not paid dividends in the last 7 fiscal years.
Who owns Neumora Therapeutics, Inc.
- Insiders 25.84%
- Institutions 61.68%
- Public & others 12.49%
- Shares outstanding 188M
- Free float 116M
Top funds holding NMRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.44M | 1.83% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.45M | 1.30% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.13M | 0.60% | +1.43% | Aug 2026 |
| Biotech Growth Ord | 1.10M | 0.59% | +52.18% | Jul 2026 |
| iShares Russell 2000 Growth ETF | 1.07M | 0.57% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 603K | 0.32% | +2.21% | Sep 2026 |
| iShares Biotechnology ETF | 600K | 0.32% | -0.19% | Oct 2026 |
| Fidelity Extended Market Index | 579K | 0.31% | +39.87% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 549K | 0.29% | +0.24% | Oct 2026 |
| iShares Micro-Cap ETF | 321K | 0.17% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 250K | 0.13% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 221K | 0.12% | 0.00% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 219K | 0.12% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 199K | 0.11% | +0.11% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 192K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 178K | 0.09% | -0.05% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 173K | 0.09% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 151K | 0.08% | 0.00% | Sep 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 147K | 0.08% | +0.21% | Oct 2026 |
| Nuveen Small Cap Blend Idx R6 | 137K | 0.07% | 0.00% | Sep 2026 |
Top institutions holding NMRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Siren, L.L.C. | 8.50M | 4.52% | 0.00% | Jun 2026 |
| BlackRock Inc | 7.79M | 4.15% | +279.29% | Jun 2026 |
| SoftBank Group Corp | 6.09M | 3.24% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.67M | 2.49% | +19.98% | Jun 2026 |
| MIC Capital Management UK LLP | 4.46M | 2.37% | 0.00% | Sep 2026 |
| FMR Inc | 3.50M | 1.86% | +0.01% | Jun 2026 |
| Wellcome Trust Ltd | 3.31M | 1.76% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 2.61M | 1.39% | +139.89% | Jun 2026 |
| ICONIQ Capital, LLC | 2.56M | 1.36% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 2.24M | 1.19% | +10.22% | Jun 2026 |
| Orbimed Advisors LLC | 2.14M | 1.14% | 0.00% | Jun 2026 |
| Lunate Capital Ltd | 2.12M | 1.13% | 0.00% | Jun 2026 |
| Boxer Capital Management, LLC | 2.00M | 1.06% | 0.00% | Jun 2026 |
| Johnson & Johnson | 1.85M | 0.98% | 0.00% | Jun 2026 |
| State Street Corp | 1.58M | 0.84% | +296.80% | Jun 2026 |
| Tudor Investment Corp Et AL | 1.36M | 0.72% | +75.80% | Jun 2026 |
| Ikarian Capital, LLC | 1.28M | 0.68% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 1.13M | 0.60% | -10.50% | Sep 2026 |
| Affinity Asset Advisors, LLC | 1.07M | 0.57% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 904K | 0.48% | -24.33% | Jun 2026 |
Neumora Therapeutics, Inc. company profile
- Company name
- Neumora Therapeutics, Inc.
- Ticker
- NMRA.US
- Exchange
- USA Stocks
- Listed since
- Sep 14, 2023
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 63
- Fiscal year end
- December
- Address
- 260 Arsenal Place, Watertown, MA, United States, 02472
- Phone
- 857 760 0900
- Website
- neumoratx.com
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Neumora Therapeutics, Inc. management
10- Mr. Paul L. BernsExecutive Chairman · born 1967
- Dr. Joshua Pinto Ph.D.President, CEO & Director · born 1984
- Dr. Daljit Singh Aurora Pharm.D.Chief Operationg & Development officer · born 1968
- Mr. Michael Lee MilliganCFO & Principal Accounting Officer · born 1973
- Dr. Nicholas Brandon Ph.D.Chief Scientific Officer · born 1975
- Mr. Pablo GersbergChief Information Officer
- Mr. Jason G. Duncan J.D.Chief Legal & Administrative Officer · born 1974
- Helen RubinsteinHead of Investor Relations
- Ms. Amy SullivanChief Human Resources Officer
- Mr. David Phillips M.B.A.Senior Vice President & Head of Quality